Tempus Acquires AI-Powered Clinical Trial Matching Platform
Tempus AI has announced the acquisition of a clinical trial matching platform Deep 6 AI, which applies artificial intelligence (AI) to streamline patient recruitment and real-world evidence generation. The acquisition adds over 750 provider sites and more than 30 million patients to Tempus' clinical trial network, according to the company’s statement.
The acquired platform uses natural language processing and machine learning to match patients to clinical trials by analyzing both structured and unstructured electronic medical record data. This includes coded data such as ICD-10 and LOINC codes, as well as unstructured data from clinical notes, lab results, and imaging findings. According to the platform’s self-reported performance, it can identify over 25% more eligible patients compared to traditional methods and help sites recruit patients up to three times faster.
Eric Lefkofsky, Founder and CEO of Tempus, stated that the platform’s infrastructure aligns with Tempus' strategy to enhance clinical connectivity and improve care delivery. He noted that the acquisition will expand Tempus' reach and improve the deployment of key applications like Next, which supports physicians in closing care gaps, and TIME, which helps patients find clinical trials:
- Tempus Next, released in April 2024, is an AI-enabled platform that integrates with electronic medical records (EMRs) to analyze clinical notes, molecular data, and imaging. The system "evaluates patient care pathways," i.e. it systematically reviews the sequence of patient interactions—from diagnosis and treatment to follow-up—and compares these processes against established clinical guidelines to detect deviations or gaps in care. Currently implemented in over 80 hospitals, the platform employs more than 60 algorithms primarily focused on cardiovascular care, with recent extensions into oncology for lung and breast cancer.
- The TIME Trial program, initiated in 2019, uses an integrated analysis of genomic and clinical data to match patients with appropriate clinical trials. The system is supported by a CAP/CLIA-certified next-generation sequencing (NGS) lab and advanced analytics platform that identifies biomarker targets from paired tumor-normal samples.
Tempus provides AI-enabled precision medicine solutions by combining a large multimodal data library with an operating system designed to facilitate personalized care and drug discovery. The integration of the new platform is intended to improve trial matching accuracy and reduce the time required to recruit patients.
Topics: AI & Digital
